VTR TI
Alternative Names: VTR-TILatest Information Update: 06 Dec 2007
At a glance
- Originator CSL Behring
- Developer CSL Behring; Curacyte AG
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Deep vein thrombosis
Most Recent Events
- 16 Jun 2004 No development reported - Preclinical for Deep vein thrombosis in Germany (unspecified route)
- 01 Apr 2004 Aventis Behring LLC has merged with ZLB Bioplasma to form ZLB Behring
- 10 Jun 2002 VitaResc Biotech has been acquired by, and merged into, Curacyte AG